Those who struggle with agonising headaches could be offered the medication.
Gerry Gajadharsingh writes:
“Calcitonin gene-related peptide (CGRP inhibitors) in the form of monoclonal antibody injections (monthly) have been offered for a while for potential migraine prevention. CGRP inhibitors block the effect of CGRP, which is a small protein that is highly prevalent in the sensory nerves that supply the head and the neck. CGRP is involved in pain transmission and levels increase during a migraine attack. It may also play a causative role in the induction of migraine attacks. CGRP inhibitors are used to manage migraines.
 There are two types of CGRP inhibitors – monoclonal antibodies and CGRP receptor antagonists (gepants). The new medication approved by nice is Rimegepant, a tablet dissolved under the tongue, initially approved in May for migraine prevention. The recent approval has been approved for use during a migraine attack.
 Research shows Rimegepant halves the frequency of moderate to severe headaches if taken as a preventative measure and causes a significant reduction in pain within two hours if taken after the attack starts.
Headache and migraine like many complex medical problems have multiple causes. Generally, when a patient starts with me on both a diagnostic and treatment approach for headache and migraine, it’s still important to have some degree of at least symptom control for these debilitating symptoms whilst the patient begins to make changes on the functional levels to address some of the multiple causes of their headache/migraine. These new drugs are not cheap, but perhaps give an option for patients where previous medications, have not really worked well.”
https://www.thehealthequation.co.uk/headache-migraine-clinic/
https://www.thehealthequation.co.uk/medical-treatments-for-headache-migraine/
Eleanor Haywood
The Times
People who suffer migraines have been given “new hope” after the “first and only” drug to quickly relieve the severe headaches was approved for the NHS.
NICE, the agency that assesses health and care practices, has announced that Rimegepant will be made available to thousands of patients with acute migraine. The medication is taken as a tablet that dissolves under the tongue, helping to ease throbbing headaches within minutes.
Pfizer produces the drug, the first in a transformative new generation of migraine treatment to be approved on the NHS. The medication blocks the release of the calcitonin gene-related peptide, or CGRP, which causes painful inflammation in blood vessels intertwined with nerve endings in the brain.
Rimegepant was approved in May for use as a preventative treatment for those with frequent migraines. The announcement means it will also be offered to those who suffered, frequent migraines, up to 150,000 people. At first it will be available only at specialist clinics, but the NHS will consider releasing it to GP surgeries to help more patients.
Robert Music, chief executive of The Migraine Trust, said the announcement brought new hope, giving “valuable options” to people who suffer migraine attacks. He added: “It will especially benefit those who have not found a treatment that works, those who get debilitating side-effects from current treatments and those with cardiovascular disease who cannot take them.
“Migraine is an incredibly misunderstood condition that can have a significant impact on all areas of life, including ability to work, maintain relationships and mental health.”
The condition affects ten million people in the UK. Women are about three times more likely to be affected than men. Symptoms include headaches, vomiting, nausea, disturbed vision, fatigue and sensitivity to light, sound and smells. Migraine attacks typically last from four hours to three days, with many people forced to take time off sick. An estimated 43 million workdays are lost each year in the UK to migraine.
Research shows Rimegepant halves the frequency of moderate to severe headaches if taken as a preventative measure and causes a significant reduction in pain within two hours if taken after the attack starts.
Nice said the drug should be available for patients who have tried at least two triptans — the usual medication for headaches or migraines — but found they were not enough. It can also be administered to those unable to take triptans or who have an intolerance, or patients who have tried nonsteroidal anti-inflammatory drugs and paracetamol.
Helen Knight, director of medicines evaluation at Nice, said migraine was an “invisible disability” that affected all aspects of life. She added: “Today’s final draft guidance addresses the high unmet need for treatment options for acute migraine, once again demonstrating our ability to ensure clinically and cost-effective medicines are available to those who need them as quickly as possible.”
The medicine was recommended in July as an option to prevent migraine for about 145,000 adults who have at least four and fewer than 15 attacks a month, with the drug taken every other day. Under the latest guidance it will also be used to relieve symptoms of a migraine, initially helping an extra 13,000 people a year.
Toby Cousens, a director at Pfizer UK, said: “Migraine can significantly interrupt people’s day-to-day lives, both personally and professionally.
“We know women are disproportionately impacted by this condition. This decision is an important milestone and further expands the use of Rimegepant for treatment of acute migraine in England. Pfizer is committed to supporting people living with migraine and we will continue to work with healthcare partners to improve care.”